被忽視的熱帶疾病診斷市場 - 全球行業規模、佔有率、趨勢、機會和預測，按疾病、按診斷方法、按服務類型、按最終用途、按地區和競爭進行細分，2020-2030 年預測

2024 年全球被忽視的熱帶疾病診斷市場價值為 62 億美元，預計在預測期內將實現令人印象深刻的成長，到 2030 年的複合年成長率為 4.09%。被忽視的熱帶疾病 (NTD) 是指一組主要影響世界低收入和熱帶或亞熱帶地區人口的傳染病。這些疾病的特點是在邊緣化和貧困社區中流行，這些社區的人們往往缺乏足夠的醫療保健、清潔水、衛生設施和預防措施。被忽視的熱帶疾病對世界上最貧窮和最邊緣化的人口影響最為嚴重，特別是那些居住在農村或城市貧民窟地區的人。這些社區通常缺乏基本的醫療服務。被忽視的熱帶疾病是由多種傳染源引起的，包括細菌、病毒、寄生蟲和原生動物。這些疾病的傳播通常與環境因素和媒介有關，例如蚊子或蒼蠅。被忽視的熱帶疾病倡導團體和宣傳活動在提高公眾和政界對這些疾病的認知方面發揮了重要作用。這為診斷和治療工作帶來了更大的支持。

主要市場促進因素

診斷學的進步

主要市場挑戰

缺乏敏感且特異的檢測

主要市場趨勢

注重早期檢測

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：顧客之聲

第5章：全球被忽視的熱帶疾病診斷市場展望

• 市場規模和預測
  • 按價值
• 市場佔有率和預測
  • 依疾病分類（登革熱、屈公病、狂犬病、布魯裡潰瘍、雅司病、淋巴絲蟲病、絛蟲病/囊蟲病、麥地那龍線蟲病等）
  • 依診斷方法（傳統、分子/現代）
  • 依服務類型（集中服務、POC 服務）
  • 依最終用途（臨床實驗室、醫院/診所、家庭醫療保健）
  • 按地區
  • 按公司分類（2024）
• 市場地圖

第 6 章：亞太地區被忽視的熱帶疾病診斷市場展望

• 市場規模和預測
• 市場佔有率和預測
• 亞太地區：國家分析
  • 印度
  • 澳洲
  • 日本
  • 韓國

第 7 章：歐洲被忽視的熱帶疾病診斷市場展望

• 市場規模和預測
• 市場佔有率和預測
• 歐洲：國家分析
  • 德國
  • 西班牙
  • 義大利
  • 英國

第 8 章：北美被忽視的熱帶疾病診斷市場展望

• 市場規模和預測
• 市場佔有率和預測
• 北美：國家分析
  • 墨西哥
  • 加拿大

第 9 章：南美洲被忽視的熱帶疾病診斷市場展望

• 市場規模和預測
• 市場佔有率和預測
• 南美洲：國家分析
  • 阿根廷
  • 哥倫比亞

第 10 章：中東和非洲被忽視的熱帶疾病診斷市場展望

• 市場規模和預測
• 市場佔有率和預測
• MEA：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 11 章：市場動態

• 驅動程式
• 挑戰

第 12 章：市場趨勢與發展

• 最新動態
• 產品發布
• 合併與收購

第 13 章：全球被忽視的熱帶疾病診斷市場：SWOT 分析

第 14 章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的力量
• 顧客的力量
• 替代產品的威脅

第 15 章： 大環境分析

第 16 章：競爭格局

• F. Hoffmann-La Roche Ltd
• Abbott Laboratories Inc.
• Thermo Fisher Scientific Inc.
• ZeptoMetrix LLC
• InBios International, Inc.
• Genome Diagnostics Pvt. Ltd.
• Omega Diagnostics Group Plc
• Coris Bioconcept
• Oscar medicare Pvt Ltd.
• DiaSys Diagnostics Systems GmbH

第 17 章：策略建議

第18章調查會社について,免責事項

Global Neglected Tropical Diseases Diagnosis Market was valued at USD 6.20 billion in 2024 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 4.09% through 2030. Neglected Tropical Diseases (NTDs) refer to a group of infectious diseases that primarily affect populations in low-income and tropical or subtropical regions of the world. These diseases are characterized by their prevalence in marginalized and impoverished communities, often lacking access to adequate healthcare, clean water, sanitation, and preventive measures. NTDs disproportionately affect the world's poorest and most marginalized populations, particularly those living in rural or urban slum areas. These communities often lack access to basic healthcare services. NTDs are caused by a variety of infectious agents, including bacteria, viruses, parasites, and protozoa. The transmission of these diseases is often linked to environmental factors and vectors, such as mosquitoes or flies. NTD advocacy groups and awareness campaigns have played a significant role in increasing public and political awareness about these diseases. This has resulted in greater support for diagnosis and treatment efforts.

Key Market Drivers

Advancements in Diagnostics

Molecular techniques such as Polymerase Chain Reaction (PCR) and Nucleic Acid Amplification Tests (NAATs) have revolutionized NTDs diagnosis. They allow for the detection of the genetic material of pathogens with high sensitivity and specificity. Molecular diagnostics are particularly useful for diseases like Chagas disease and Leishmaniasis. For instance, according to a 2024 NCBI article, advancements in artificial intelligence are enhancing medical computer-aided diagnosis, improving accuracy, efficiency, and early disease detection for better patient outcomes.

Also, in May 2022, medical technology company Anitoa Systems launched a portable RT-PCR test for dengue virus detection, expanding its Maverick RT-PCR device line. This multiplex test detects multiple target genes linked to severe dengue, ensuring early and accurate diagnosis. Point-of-Care Testing (POCT) devices have been developed for various NTDs, enabling rapid and on-site diagnosis. These portable devices are especially valuable in remote and resource-limited settings where access to centralized laboratories is limited. Examples include rapid diagnostic tests for malaria and dengue. Serological tests detect specific antibodies produced by the immune system in response to infection. Advances in serological assays have improved their accuracy and made them more widely available for diagnosing diseases like schistosomiasis and lymphatic filariasis. Some NTDs can be diagnosed by detecting specific antigens produced by the pathogens. Antigen detection tests are valuable for diseases like African sleeping sickness and urinary schistosomiasis.

Key Market Challenges

Lack of Sensitive and Specific Tests

Many NTDs share symptoms with other diseases or have multiple stages, making accurate diagnosis difficult. When sensitive and specific tests are lacking, there's a higher risk of misdiagnosis or underdiagnosis, leading to delayed or inadequate treatment. Accurate diagnosis is essential for determining the appropriate treatment regimen. Without sensitive and specific tests, healthcare providers may resort to empirical treatment, which can result in unnecessary healthcare costs and potential drug resistance. NTDs control and elimination programs rely on accurate data to target affected populations effectively. Inaccurate diagnosis can lead to misallocation of resources, potentially slowing down progress in controlling these diseases. For tracking the prevalence and distribution of NTDs, sensitive and specific tests are crucial. Inaccurate diagnostic tools can lead to inaccurate disease surveillance data, hindering the ability to detect outbreaks or changes in disease patterns. Diagnostic tools are fundamental in research efforts related to NTDs, including drug and vaccine development. Insensitive or nonspecific tests can slow down the research process and hinder the identification of potential therapeutic targets. Patients may undergo multiple tests, sometimes invasive, to confirm an NTD diagnosis due to the lack of definitive tests. This can result in a physical and psychological burden on affected individuals. Limited healthcare resources in endemic regions should be used efficiently. Sensitive and specific tests are essential for targeting interventions to those who need them most, thereby optimizing resource allocation.

Key Market Trends

Focus on Early Detection

Early detection allows for prompt initiation of treatment, which can lead to better outcomes for patients. For many NTDs, early treatment can prevent disease progression and complications. Early diagnosis and treatment can help break the cycle of transmission of NTDs. By identifying and treating infected individuals early, there is a reduced risk of spreading the disease to others through vectors or direct contact. Some NTDs, such as lymphatic filariasis and leprosy, can cause disabling conditions if not treated early. Early detection and intervention can prevent or reduce disability and improve the quality of life for affected individuals. Early detection can be cost-effective in the long run. It reduces the need for more extensive and expensive treatments that may be required if NTDs are diagnosed at a later stage. Timely diagnosis contributes to the success of NTDs control and elimination programs. Early detection allows for more targeted and efficient interventions, which can accelerate progress toward achieving disease control goals. Some NTDs are associated with social stigma and discrimination. Early diagnosis and treatment can help individuals avoid the social consequences of living with untreated NTDs. Advances in point-of-care diagnostic technologies make it possible to diagnose NTDs quickly and accurately in resource-limited settings, enabling immediate treatment and reducing the need for follow-up visits.

Key Market Players

• F. Hoffmann-La Roche Ltd
• Abbott Laboratories Ltd.
• Thermo Fisher Scientific Inc.
• ZeptoMetrix LLC
• InBios International, Inc.
• DiaSys Diagnostics Systems GmbH
• Genome Diagnostics Pvt. Ltd.
• Omega Diagnostics Group Plc
• Oscar Medicare Pvt Ltd.
• Coris BioConcept

Report Scope:

In this report, the Global Neglected Tropical Diseases Diagnosis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Neglected Tropical Diseases Diagnosis Market, By Disease:

• Dengue
• Chikungunya
• Rabies
• Buruli Ulcer
• Yaws
• Lymphatic Filariasis
• Taeniasis/Cysticercosis
• Dracunculiasis
• Others

Neglected Tropical Diseases Diagnosis Market, By Diagnostic Method:

• Conventional
• Molecular/Modern

Neglected Tropical Diseases Diagnosis Market, By Service Type:

• Centralized Service
• POC Service

Neglected Tropical Diseases Diagnosis Market, By End-Use:

• Clinical Labs
• Hospital/Clinics
• Home Healthcare

Neglected Tropical Diseases Diagnosis Market, By region:

• North America
  • United States
  • Canada
  • Mexico
• Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
• Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Neglected Tropical Diseases Diagnosis Market.

Available Customizations:

Global Neglected Tropical Diseases Diagnosis Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Neglected Tropical Diseases Diagnosis Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Disease (Dengue, Chikungunya, Rabies, Buruli Ulcer, Yaws, Lymphatic Filariasis, Taeniasis/Cysticercosis, Dracunculiasis, others)
  • 5.2.2. By Diagnostic Method (Conventional, Molecular/Modern)
  • 5.2.3. By Service Type (Centralized Service, POC Service)
  • 5.2.4. By End Use (Clinical Labs, Hospital/Clinics, Home Healthcare)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Market Map

6. Asia Pacific Neglected Tropical Diseases Diagnosis Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Disease
  • 6.2.2. By Diagnostic Method
  • 6.2.3. By Service Type
  • 6.2.4. By End Use
  • 6.2.5. By Country
• 6.3. Asia Pacific: Country Analysis
  • 6.3.1. China Neglected Tropical Diseases Diagnosis Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Disease
      • 6.3.1.2.2. By Diagnostic Method
      • 6.3.1.2.3. By Service Type
      • 6.3.1.2.4. By End Use
  • 6.3.2. India Neglected Tropical Diseases Diagnosis Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Disease
      • 6.3.2.2.2. By Diagnostic Method
      • 6.3.2.2.3. By Service Type
      • 6.3.2.2.4. By End Use
  • 6.3.3. Australia Neglected Tropical Diseases Diagnosis Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Disease
      • 6.3.3.2.2. By Diagnostic Method
      • 6.3.3.2.3. By Service Type
      • 6.3.3.2.4. By End Use
  • 6.3.4. Japan Neglected Tropical Diseases Diagnosis Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Disease
      • 6.3.4.2.2. By Diagnostic Method
      • 6.3.4.2.3. By Service Type
      • 6.3.4.2.4. By End Use
  • 6.3.5. South Korea Neglected Tropical Diseases Diagnosis Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Disease
      • 6.3.5.2.2. By Diagnostic Method
      • 6.3.5.2.3. By Service Type
      • 6.3.5.2.4. By End Use

7. Europe Neglected Tropical Diseases Diagnosis Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Disease
  • 7.2.2. By Diagnostic Method
  • 7.2.3. By Service Type
  • 7.2.4. By End Use
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Neglected Tropical Diseases Diagnosis Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Disease
      • 7.3.1.2.2. By Diagnostic Method
      • 7.3.1.2.3. By Service Type
      • 7.3.1.2.4. By End Use
  • 7.3.2. Germany Neglected Tropical Diseases Diagnosis Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Disease
      • 7.3.2.2.2. By Diagnostic Method
      • 7.3.2.2.3. By Service Type
      • 7.3.2.2.4. By End Use
  • 7.3.3. Spain Neglected Tropical Diseases Diagnosis Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Disease
      • 7.3.3.2.2. By Diagnostic Method
      • 7.3.3.2.3. By Service Type
      • 7.3.3.2.4. By End Use
  • 7.3.4. Italy Neglected Tropical Diseases Diagnosis Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Disease
      • 7.3.4.2.2. By Diagnostic Method
      • 7.3.4.2.3. By Service Type
      • 7.3.4.2.4. By End Use
  • 7.3.5. United Kingdom Neglected Tropical Diseases Diagnosis Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Disease
      • 7.3.5.2.2. By Diagnostic Method
      • 7.3.5.2.3. By Service Type
      • 7.3.5.2.4. By End Use

8. North America Neglected Tropical Diseases Diagnosis Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Disease
  • 8.2.2. By Diagnostic Method
  • 8.2.3. By Service Type
  • 8.2.4. By End Use
  • 8.2.5. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States Neglected Tropical Diseases Diagnosis Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Disease
      • 8.3.1.2.2. By Diagnostic Method
      • 8.3.1.2.3. By Service Type
      • 8.3.1.2.4. By End Use
  • 8.3.2. Mexico Neglected Tropical Diseases Diagnosis Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Disease
      • 8.3.2.2.2. By Diagnostic Method
      • 8.3.2.2.3. By Service Type
      • 8.3.2.2.4. By End Use
  • 8.3.3. Canada Neglected Tropical Diseases Diagnosis Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Disease
      • 8.3.3.2.2. By Diagnostic Method
      • 8.3.3.2.3. By Service Type
      • 8.3.3.2.4. By End Use

9. South America Neglected Tropical Diseases Diagnosis Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Disease
  • 9.2.2. By Diagnostic Method
  • 9.2.3. By Service Type
  • 9.2.4. By End Use
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Neglected Tropical Diseases Diagnosis Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Disease
      • 9.3.1.2.2. By Diagnostic Method
      • 9.3.1.2.3. By Service Type
      • 9.3.1.2.4. By End Use
  • 9.3.2. Argentina Neglected Tropical Diseases Diagnosis Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Disease
      • 9.3.2.2.2. By Diagnostic Method
      • 9.3.2.2.3. By Service Type
      • 9.3.2.2.4. By End Use
  • 9.3.3. Colombia Neglected Tropical Diseases Diagnosis Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Disease
      • 9.3.3.2.2. By Diagnostic Method
      • 9.3.3.2.3. By Service Type
      • 9.3.3.2.4. By End Use

10. Middle East and Africa Neglected Tropical Diseases Diagnosis Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Disease
  • 10.2.2. By Diagnostic Method
  • 10.2.3. By Service Type
  • 10.2.4. By End Use
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Neglected Tropical Diseases Diagnosis Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Disease
      • 10.3.1.2.2. By Diagnostic Method
      • 10.3.1.2.3. By Service Type
      • 10.3.1.2.4. By End Use
  • 10.3.2. Saudi Arabia Neglected Tropical Diseases Diagnosis Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Disease
      • 10.3.2.2.2. By Diagnostic Method
      • 10.3.2.2.3. By Service Type
      • 10.3.2.2.4. By End Use
  • 10.3.3. UAE Neglected Tropical Diseases Diagnosis Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Disease
      • 10.3.3.2.2. By Diagnostic Method
      • 10.3.3.2.3. By Service Type
      • 10.3.3.2.4. By End Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Neglected Tropical Diseases Diagnosis Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

• 16.1. F. Hoffmann-La Roche Ltd
  • 16.1.1. Business Overview
  • 16.1.2. Company Snapshot
  • 16.1.3. Products & Services
  • 16.1.4. Financials (In case of listed companies)
  • 16.1.5. Recent Developments
  • 16.1.6. SWOT Analysis
• 16.2. Abbott Laboratories Inc.
  • 16.2.1. Business Overview
  • 16.2.2. Company Snapshot
  • 16.2.3. Products & Services
  • 16.2.4. Financials (In case of listed companies)
  • 16.2.5. Recent Developments
  • 16.2.6. SWOT Analysis
• 16.3. Thermo Fisher Scientific Inc.
  • 16.3.1. Business Overview
  • 16.3.2. Company Snapshot
  • 16.3.3. Products & Services
  • 16.3.4. Financials (In case of listed companies)
  • 16.3.5. Recent Developments
  • 16.3.6. SWOT Analysis
• 16.4. ZeptoMetrix LLC
  • 16.4.1. Business Overview
  • 16.4.2. Company Snapshot
  • 16.4.3. Products & Services
  • 16.4.4. Financials (In case of listed companies)
  • 16.4.5. Recent Developments
  • 16.4.6. SWOT Analysis
• 16.5. InBios International, Inc.
  • 16.5.1. Business Overview
  • 16.5.2. Company Snapshot
  • 16.5.3. Products & Services
  • 16.5.4. Financials (In case of listed companies)
  • 16.5.5. Recent Developments
  • 16.5.6. SWOT Analysis
• 16.6. Genome Diagnostics Pvt. Ltd.
  • 16.6.1. Business Overview
  • 16.6.2. Company Snapshot
  • 16.6.3. Products & Services
  • 16.6.4. Financials (In case of listed companies)
  • 16.6.5. Recent Developments
  • 16.6.6. SWOT Analysis
• 16.7. Omega Diagnostics Group Plc
  • 16.7.1. Business Overview
  • 16.7.2. Company Snapshot
  • 16.7.3. Products & Services
  • 16.7.4. Financials (In case of listed companies)
  • 16.7.5. Recent Developments
  • 16.7.6. SWOT Analysis
• 16.8. Coris Bioconcept
  • 16.8.1. Business Overview
  • 16.8.2. Company Snapshot
  • 16.8.3. Products & Services
  • 16.8.4. Financials (In case of listed companies)
  • 16.8.5. Recent Developments
  • 16.8.6. SWOT Analysis
• 16.9. Oscar medicare Pvt Ltd.
  • 16.9.1. Business Overview
  • 16.9.2. Company Snapshot
  • 16.9.3. Products & Services
  • 16.9.4. Financials (In case of listed companies)
  • 16.9.5. Recent Developments
  • 16.9.6. SWOT Analysis
• 16.10. DiaSys Diagnostics Systems GmbH
  • 16.10.1. Business Overview
  • 16.10.2. Company Snapshot
  • 16.10.3. Products & Services
  • 16.10.4. Financials (In case of listed companies)
  • 16.10.5. Recent Developments
  • 16.10.6. SWOT Analysis

17. Strategic Recommendations

18. About Us & Disclaimer